Clinical trials: Stage I Skin Cancer
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Solid Tumor, Extensive-stage Small-cell Lung Cancer
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
An open-label, two-part Phase I/Ib study of RP12146 in adult patients with locally advanced or metastatic solid tumors. The first part (Part 1) is a Phase I dose-escalation, 3+3 design, open-label, MTD determination study and…
- Conditions
- Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT05002868
- Testing
- RP12146
- Where
- 6 sites in Czechia, Poland
- Volunteers
- 23 people
- Sponsor
- Rhizen Pharmaceuticals SA
Medical Oncology
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5…
- Trial name
- NCT02366949
- Testing
- BAY1217389, Paclitaxel
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 75 people
- Sponsor
- Bayer
Breast Cancer
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
This is a research study to evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer.
- Trial name
- DIGNITY (NCT00826085)
- Testing
- ThermoDox in combination with Microwave Hyperthermia (heat)
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Imunon
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00033228
- Testing
- MKC1106-MT
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Solid Tumor, Adult
Study of DF1001 in Patients With Advanced Solid Tumors
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT04143711
- Testing
- DF1001, Nivolumab, Nab paclitaxel
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Dragonfly Therapeutics
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Solid Tumor, Breast Cancer
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502.
- Trial name
- NCT03944499
- Testing
- FS-1502
- Where
- 12 sites in China
- Volunteers
- 161 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Actinic Keratosis
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by histology.
- Trial name
- NCT01387711
- Testing
- PEP005 (Ingenol mebutat Gel, 0.05 %)
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- LEO Pharma
Melanoma
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
The purpose of this study is to determine whether the combination of interleukin-21 (IL-21) and Ipilimumab in subjects with melanoma is safe, and provide preliminary information on the clinical benefits of the combination…
- Trial name
- NCT01489059
- Testing
- BMS-982470 (recombinant interleukin-21), Ipilimumab
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 42 people
- Sponsor
- Bristol-Myers Squibb
Unresectable Stage III or Stage IV Melanoma
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
This study will evaluate the safety, tolerability and pharmacokinetics of CR011-vcMMAE in patients who have unresectable stage III or stage IV melanoma and have failed no more than 1 line of prior cytotoxic therapy.
- Trial name
- NCT00412828
- Testing
- CR011-vcMMAE
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- CuraGen Corporation
Radiation-induced Dermatitis
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with…
- Trial name
- NCT01714973
- Testing
- ST266
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Wart; External Genital Organs, Condyloma Acuminata
Safety and Efficacy Study to Test Topical AS101 for External Genital Warts
The purpose of this study is to determine whether the improved topical ointment formulation, AS101, is safe and effective in the treatment of external genital warts in females.
- Trial name
- NCT01555112
- Testing
- Topical AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
BRAF V600 Mutation, Unresectable Melanoma
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation.
- Conditions
- BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
- Trial name
- NCT04759846
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in Czechia, Italy and 1 more
- Sponsor
- Pierre Fabre Medicament
Melanoma
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
To evaluate the safety and tolerability of intradermal injections of IMM-101 (Heat-killed Mycobacterium obuense) in melanoma cancer patients.
- Trial name
- NCT01308762
- Testing
- Heat killed whole cell M. obuense (IMM-101) 0.1 mg, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Immodulon Therapeutics Ltd
ER-positive, HER2-negative Breast Cancer
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
The Sponsor is developing the test medicine, AZD9833 for the potential treatment of estrogen receptor (ER)-positive breast cancer.
- Trial name
- NCT05364255
- Testing
- [14C]AZD9833 Oral Solution, 75 mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Colorectal Cancer, Colon Cancer
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms
- Trial name
- NCT00041652
- Testing
- hMN14 (labetuzumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences